Infections, Human Immunodeficiency Virus and Herpesviridae Clinical Trial
Official title:
An Observer- and Subject-Blinded, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
A single dose escalation study to determine the safety, tolerability, and pharmacokinetic profile of intramuscular and subcutaneous injections of GSK1265744 long acting parenteral (LAP) in healthy subjects. This study consists of a screening visit, a single injection, and follow-up evaluations for a minimum of 12 weeks following the injection.
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship ;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01209065 -
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
|
Phase 1 | |
Completed |
NCT01209117 -
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
|
Phase 1 | |
Completed |
NCT01098526 -
GSK1349572 Drug Interaction Study With Efavirenz
|
Phase 1 | |
Completed |
NCT01382238 -
Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir
|
Phase 1 |